“The third quarter was a pivotal period for Galecto (GLTO) highlighted by the completion of a strategic review to prioritize oncology and liver diseases and subsequent acquisition of BRM-1420, a novel, dual ENL-YEATS, and FLT3 inhibitor for multiple genetic subsets of acute myeloid leukemia (AML) that further strengthens our existing portfolio of first-in-class small molecule agents,” said Dr. Hans Schambye, CEO of Galecto. “As we complete the work required to advance BRM-1420 to clinical trials, our goal is to realize its potential in addressing the needs of underserved AML patient populations. We are also excited about the continued development of GB1211, currently being evaluated in two clinical studies for various oncology indications.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLTO:
- Galecto price target raised to $10 from $9 at Oppenheimer
- Galecto Appoints Dr. Amy Wechsler to Board
- Galecto announces the appointment of Wechsler to its Board of Directors
- Arcadium confirms Rio approach, Apollo funds to acquire Barnes: Morning Buzz
- Galecto completes strategic review, will focus on oncology, liver disease